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The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the chymotrypsin-like activity at
the β5-subunit of proteasome (PSMB5), has marked efficacy against multiple myeloma and several non-Hodgkin’s
lymphoma subtypes, and has a potential therapeutic role against other malignancy diseases. However, intrinsic and
acquired resistance to bortezomib may limit its efficacy. In this article, we discuss recent advances in the molecular
understanding of bortezomib resistance. Resistance mechanisms discussed include mutations of PSMB5 and the
up-regulation of proteasome subunits, alterations of gene and protein expression in stress response, cell survival
and antiapoptotic pathways, and multidrug resistance.
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The ubiquitin-proteasome pathway plays an essential role
in the degradation of cellular proteins involved in a variety
of cellular processes, including transcriptional regulation,
cell cycle progression, proliferation, and apoptosis [1]. The
proteasome has been well recognized as a valid target for
anti-tumor therapy [2]. The proteasome is a 26S enzyme
complex that comprised of 20S core complex and 19S
regulatory complex (Figure 1A). Within the 20S core, pro-
teins are degraded to small peptides. The 20S proteasome
core has chymotrypsin-like, trypsin-like, and peptidyl
glutamyl-like activities that are associated with three dis-
tinct units: β5, β2, β1, respectively. Chymotrypsin-like ac-
tivity at proteasome β5 subunit (PSMB5) is associated
with the rate-limiting step of proteolysis [3,4] (Figure 1B).
It is conformationally flexible with active catalytic sites lo-
cated on the inner surface of the cylinder where protein
substrates bind [5-7]. Another form of the proteasome
that is primarily expressed in cells of hematopoietic origin
and cells exposed to inflammatory cytokines, known as
the immunoproteasome (i20S), has the three catalytic ac-
tivities represented by LMP7 (β5i), LMP2 (β1i), and
MECL1 (β2i), which are more efficient in regulating
antigen processing [8].* Correspondence: jmwang@medmail.com.cn
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reproduction in any medium, provided the orInhibition of the proteasome results in perturbation of
intracellular protein homeostasis by accumulation of the
poly-ubiquitinated proteins, subsequently inducing cellular
stress and apoptosis. Numerous proteasome inhibitors
have been developed and described. Bortezomib (PS-341,
Velcade), a boronic dipeptide which reversibly inhibit the
chymotrypsin-like activity at the β5-subunit and to a lesser
extent inhibit the trypsin-like activity at the β1-subunit, is
the first proteasome inhibitor approved by FDA of the
United States. Bortezomib induces apoptosis in a wide va-
riety of cancer cell lines and other transformed cells, yet
has relatively few toxic effects on normal cells [2,9,10].
Clinical studies have demonstrated the safety and promi-
sing efficacy of bortezomib as the single-agent or com-
bined with other drugs against multiple myeloma (MM)
[11,12], as well as in several non-Hodgkin’s lymphoma sub-
types [13]. Bortezomib can also potentiate leukemia cell
apoptosis and has a potential therapeutic role against
leukemia, either alone or in combination with chemothe-
rapy [14,15].
However, there are some patients who do not respond
to therapy or respond briefly, then relapse. Here we will
review the development of study in resistance mecha-
nisms of bortezomib.Point mutation or over-expression of PSMB5 gene
To shed light on the mechanisms of acquired resistance
to bortezomib after drug exposure, we establishedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The structure of 26 s proteasome. The proteasome is a
26S enzyme complex that comprised of core 20S catalytic complex
and 19S regulatory complex (A). The 20S proteasome core has
chymotrypsin-like, trypsin-like, and peptidyl glutamyl-like activities
that are associated with three distinct units: β5, β2, β1, respectively.
Chymotrypsin-like activity at proteasome β5 subunit (PSMB5) is
associated with the rate-limiting step of proteolysis. Proteasome
inhibitor bortezomib (Bort) mainly inhibit the chymotrypsin-like
activity at the PSMB5 (B).
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cells JurkatB, from the parental Jurkat cell line by repeated
drug exposure and selection. First we confirmed G322A
point mutation of PSMB5 gene confer bortezomib resist-
ance to JurkatB cells. The inhibition rate of chymotrypsin-
like activity in JurkatB cells was significantly decreased
compared with parental Jurkat cells after bortezomib
treatment. The retro-virally transduced Jurkat-mPSMB5
cells acquired a bortezomib-resistant phenotype due to
the expression of G322A mutated PSMB5, reiterating the
idea that the PSMB5 mutation is an important mechanism
of bortezomib resistance [16]. Then JurkatB cells were se-
lected with bortezomib at higher concentrations for ex-
tended periods of time, revealing novel PSMB5 mutants:
C323 T mutant and G322A, C326 T conjoined mutant.
The inhibitory effect of bortezomib on chymotrypsin-like
activity was the weakest in JurkatB-G322A/C326T cells,
and the strongest in JurkatB-G322A cells, with JurkatB-
C323T cells falling in between. So the C323 T mutation
and G322A, C326 T conjoined mutation of PSMB5 gene
confer stronger bortezomib resistance than G322A muta-
tion in JurkatB cells. The crystal structure in yeast illus-
trates that specific interactions are formed between thepyrazine-2-carboxyl side chain of bortezomib and residues
of the PSMB5 specific pocket (S1 pocket). In the case of
the chymotryptic-like active site, the carbonyl oxygen of
bortezomib interact with PSMB5 Ala49 N and PSMB5
Ala50 N by a tight hydrogen bonding network. Computer
modeling of the Ala49Thr-mutated PSMB5 protein
resulting from the G322A mutation suggests that a con-
formation change occurs that may disrupt contacts be-
tween the chymotrypsin-like active site and bortezomib.
The G322A, C323 T mutation and the G322A, C326 T
conjoined mutation causes amino acid substitutions at
position 108 and/or 109 of precursor PSMB5 protein
(Ala108Thr and Ala109Val), which translates to Ala49Thr
and/or Ala50Val of functional PSMB5 protein. So Ala49
and Ala50 of the PSMB5 protein are key positions relative
to the inhibitory effect of bortezomib on chymotrypsin-
like activity. Mutations in the PSMB5 gene that result in
substitutions of these amino acid residues can confer va-
rying bortezomib resistance [17].
Following our study, Oerlemans et al. also confirmed
G322A PSMB5 mutation which resulted in Ala49Thr
substitution in bortezomib resistant human monocytic/
macrophage THP1/BTZ cells established by exposure to
stepwise increasing concentrations of bortezomib [18].
Franke et al. confirmed the G322A, C323T PSMB5 mu-
tations in bortezomib-resistant MM cell line 8226/BTZ
and acute lymphoblastic leukemia cell line CEM/BTZ
selected by bortezomib exposure [19]. Ri et al. also
established two bortezomib-resistant MM cell lines
KMS-11/BTZ and OPM-2/BTZ, and demonstrated these
resistant MM cells have G322A mutation of PSMB5
gene. KMS-11 parental cells transfected to express mu-
tated PSMB5 also showed reduced bortezomib induced
apoptosis compared with those expressing wild-type
PSMB5 or the parental cells. Expression of mutated
PSMB5 was associated with the prevention of the accu-
mulation of unfolded proteins and subsequent excessive
endoplasmic reticulum (ER) stress which triggers apop-
totic signals [20]. Otherwise, Franke et al. also identified
G332T (Cys52Phe substitution) mutation in CEM/BTZ
cells, G311T (Met45Ile substitution), A310G (Met45Val
substitution) in THP1/BTZ cells and A247G (Thr21Ala
substitution) mutation in 8226/BTZ cells [19]. Recently,
de Wilt et al. confirmed acquired bortezomib resistance
in non-small cell lung cancer (NSCLC) cell lines is asso-
ciated with PSMB5 mutations resulting in Ala49Thr,
Met45Val and Cys52Phe substitutions [21].
The vast majority of these mutated residues are around
the S1 specificity pocket of the PSMB5. This S1 specificity
pocket is mainly responsible for recognizing the peptide
bond of the substrate. The Thr21Ala, Ala49Thr and
Ala50Val substitutions in the bortezomib-binding pocket
at the PSMB5 are directly involved in bortezomib binding
to PSMB5 (Figure 2). Cys52Phe, Met45Ile substitutions in
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PSMB5 are indirectly involved in bortezomib binding.
Silico data suggest that all acquired mutations decrease
the affinity of the PSMB5, particularly of the S1-binding
pocket, to bortezomb (Figure 3, [22], [23]).
Otherwise, Suzuki et al. established clonal bortezomib
resistant isolates of HT-29 adenocarcinoma cells adapted
to continuous exposure of bortezomib. Two novel and
distinct mutations in the PSMB5, Cys63Phe, located dis-
tal to the binding site in a helix critical for drug binding,
and Arg24Cys, found in the propeptide region were
found in all resistant clones. The portion containing
Arg24 is required for proper subunit processing. It is
possible that the altered recovery of proteasome activity
following bortezomib exposure is a result of altered β5
processing [24]. The mutation Arg24Cys is a natural
variant, with a frequency 5 times higher in patients with
MM than in the general population reported by Wang et
al [25]. Cys63 is housed in the same helix as Ala49/50,
residues critical for bortezomib binding as described
previously (Figure 3). The Cys63Phe mutation leads to a
shift in the angle of the helix with respect to the active
site, therefore, likely affects the binding of bortezomib to
PSMB5. Of further note was the presence of a mutation
in the propeptide portion of LMP7 (Phe50Ile) in 2 of 3
bortezomib resistant clonal isolates [24].
Interestingly, Kale et al. have observed Met45Val and
Ala49Val mutations located within the S1 binding pocket
of proteasome β-subunit in the irreversible proteasome in-
hibitor salinosporamide, producing marine actinobacterium
Salinispora tropica, in which all seven β-subunits are identi-
cal. The mutant was markedly resistant to proteasomeFigure 2 Interaction model of bortezomib with active site of β5 subu
β5 subunit of proteasome (PSMB5). Ala49, Ala50, Thr21 participate in the ti
with the active site of PSMB5.inhibitor bortezomib and salinosporamide than the
wildtype Salinispora tropica. Met45Val played little role in
resistance, whereas Ala49Val affected inhibitor resistance,
substrate specificity, and prosequence cleavage. While the
subunit topology and cellular function of the 20S prote-
asome in humans and actinobacteria are not identical, it is
striking that equivalent mutations are utilized in both sys-
tems to achieve proteasome inhibitor resistance [26].
However, no mutations in PSMB5 have been detected
in myeloma patients refractory to, or relapsed from,
bortezomib treatment [27,28]. To further investigate the
role of mutations of the PSMB5 in bortezomib resistance
of clinical patients, a larger number of patients who have
acquired bortezomib resistance during or after bortezomib
treatment are required.
Our previous study also showed that the PSMB5 gene
was over-expressed in some resistant JurkatB cells ac-
companied by increased chymotrypsin-like activity. We
also found upregulated expression of the PSMB5 gene
contributed to drug resistance in patient with multiple
myeloma when treated with bortezomib-based regimen
[29]. Similar discovery was reported by Oerlemans et al.
in an acquired bortezomib resistant human monocytic/
macrophage THP1/BTZ cell line [18] and by Balsas et al.
in an acquired bortezomib resistant myeloma cell line
[30]. Therefore, over-expression of the PSMB5 gene in
response to drug stress, contributing to the increased
chymotrypsinlike activity, is an important mechanism of
acquired bortezomib resistance. Study of Yang YM et al.
demonstrated that the PSMB5 downregulation by
Ga12/13 inhibition enhances the anticancer effect of
bortezomib, which may be of use to improve bortezomibnit of proteasome. Ala49, Ala50, Thr21 cited at the specific pocket of
ght hydrogen-bonding network, when bortezomib (in blue) interacts
Figure 3 The 3D protein-backbone structure of the β5 subunit of proteasome. The 3D model of protein-backbone structure of the β5
subunit of proteasome (PSMB5) consults the yeast proteasomal crystal structure in complex with bortezomib [22]; the bovine proteasomal crystal
structure [23]; models made by Franke et al [19],. de Wilt et al [21]. and Suzuki et al [24]. Mutation sites are depicted in red. P1, substrate side
chain 1; S1, specificity binding pocket 1.
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study by Kraus et al. showed that the proteasomal acti-
vity profile varies in primary leukemia cells, and that
the pattern of proteasomal subunit activity influences
the sensitivity of hematologic malignancies toward
bortezomib [32]. de Wilt et al. also demonstrated
that high basal levels of proteasome activity correlate with
intrinsic bortezomib resistance in various NSCLC cell
lines, and acquired bortezomib resistance in NSCLC, is
associated with proteasome subunit overexpression [21].
Proteasome activity and levels of both the constitutive and
immunoproteasome were increased in bortezomib resist-
ant HT-29 adenocarcinoma cells, which correlated to an
increase in subunit gene expression [24].
The results of these studies are important for the de-
sign of novel proteasome inhibitors without cross-
resistance with bortezomib.
Study of de Wilt et al. showed there was obvious cross-
resistance in some of the bortezomib resistant NSCLC cell
lines harboring PSMB5 mutations to other proteasome in-
hibitors specifically targeting β-subunits (including
MG132 which targets all β subunits of the proteasome, ir-
reversible proteasome inhibitors, such as carfilzomib and
an derivative ONX 0912). Carfilzomib, an irreversible
tetrapeptide epoxyketone proteasome inhibitor, exhibits
more specificity for the chymotrypsin-like activity at the
β5 and immuno-β5-subunit than other proteasome inhibi-
tor, and appears to have a more favorable toxicity profile.
ONX 0912, a tripeptide epoxyketone, is an orally availableanalogue of carfilzomib. But there was no obvious cross-
resistance in these bortezomib resistant NSCLC cells to
the novel α7-subunit-specific proteasome inhibitor (5-
amino-8-hydroxyquinoline, 5-HAQ) [21]. This is similar
to study of Franke et al. Bortezomib resistant (170-fold)
acute lymphoblastic leukemia CEM/BTZ cells gained a
cross-resistance to carfilzomib (39-fold). THP1 myeloid
sublines with acquired resistance to bortezomib (54–235
fold) caused by mutations in the PSMB5 gene displayed
less pronounced cross-resistance to carfilzomib (9–32 fold)
[19]. But, irreversible proteasome inhibitor carfilzomib
showed only a 3–4 fold decrease in cytotoxic potential
in the bortezomib resistant HT-29 adenocarcinoma
cells, another irreversible proteasome inhibitor, LLL-Bor,
was also equivalently cytotoxic to both resistant and
parental cells, while the bortezomib resistant cells
remained refractory to the reversible inhibitor MG132
[24]. These results may have important clinical implica-
tions. The second-generation proteasome inhibitors di-
rected against α subunits can overcome this bortezomib
resistance in cells harboring PSMB5 mutations, hence of-
fering a potential future treatment modality. Resistance to
bortezomib, can be partially overcome with irreversible in-
hibitors, suggesting prolonged proteasome inhibition in-
duces a more potent anti-tumor response. An open-label,
single-arm, phase 2 study showed single-agent carfilzomib
had activity in patients with relapsed and/or refractory
MM who had received prior treatment with bortezomib
[33]. Moreover, some studies showed ubiquitination
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protesome inhibitor, the disregulation of cellular protein
destruction, with an alternative target. Thus, inhibition of
the ubiquitination pathway enzyme is a novel strategy to
overcome bortezomib resistance [34-36].
Alterations of gene and protein expression in stress
response,cell survival and antiapoptotic pathways
Bortezomib, inhibiting the chymotrypsin-like activity at
the PSMB5, blocked the degradation of the poly-
ubiquitinated proteins such as IkB-.alpha;, a negative regu-
lator of the nuclear factor (NF)-κB pathway, and unfolded
or oxidatively modified proteins followed by endoplasmic
reticulum (ER) stress and effects on the tumor microenvi-
ronment associated apoptosis [4]. Thus, the upregulation
of gene and protein expression in stress response and cell
survival, antiapoptotic pathways can confer tumor cells
bortezomib resistance.
Shringarpure et al. demonstrated that heat shock pro-
teins (HSPs: HSP70, HSP27, HSP90) and other proteins
with chaperone-like functions had higher expression
levels in primary bortezomib resistant diffuse large B-
cell lymphoma cell line SUDHL-4 cells than in
bortezomib-sensitive SUDHL-6 cells. Blocking Hsp27
using an antisense strategy restores the apoptotic re-
sponse to bortezomib in DHL4 cells; conversely, ectopic
expression of wild-type Hsp27 renders bortezomib-
sensitive DHL6 cells resistant to bortezomib. These data
confirm that higher expression of HSPs and other chap-
erones is associated with resistance to bortezomib. The
increased levels of chaperones including Hsp27 also pre-
vent the activation of the unfolded protein response in
ER and subsequent apoptosis [37-39]. Increased expres-
sion of HSP27 was also noted in bortezomib resistant
HT-29 adenocarcinoma cells [24].
Bortezomib induced a significant upregulation of ATF
3, ATF 4, ATF 5, c-Jun and Jun D proto-oncogene in
SUDHL-6 cells. Activation of JNK-1 in response to
bortezomib was confirmed by an increase in phospho-
JNK1 as well as increased phosphorylation of JNK sub-
strates, c-Jun and ATF-2 in sensitive SUDHL-6 cells.
However, no similar activation of JNK-1 in response to
bortezomib in resistant SUDHL-4 cells was observed.
The expression of transcription factor 4 (TCF-4) was 15-
fold higher in resistant SUDHL-4 cells compared with
sensitive SUDHL-6 cell. TCF-4 is a central player in the
Wnt signalling pathway that has been implicated in cancer
development, differentiation, and drug resistance. Poten-
tial downstream target genes of the TCF-4/β-catenin com-
plex, cyclin D1 and c-myc, were also upregulated in
SUDHL-4 cells. So the differential gene expression profiles
of SUDHL-4 and SUDHL-6 cells have confirmed the acti-
vation of pathways mediating bortezomib induced apop-
tosis in sensitive SUDHL-6 cells, but not in resistantSUDHL-4 cells. These studies will provide valuable in-
sights into the mechanisms of drug resistance to
bortezomib, and identify molecular targets to overcome
bortezomib resistance in haematological malignancies. β-
catenin, the key protein in canonical Wnt pathway, de-
grades via ubiquitin-proteasome pathway. Study of Zhou
et al. found that myeloma cell lines with higher β-catenin
level are less sensitive to bortezomib, and combination
treatment of low dose 2-methoxyestradiol, arsenic trioxide
and bortezomib can reduce β-catenin accumulation and
enhance the sensitivity to bortezomib [36,39,40].
Interleukin-6 and insulin-like growth factor (IGF-1) in
the microenvironment can also maintain cell growth,
and confer resistance to bortezomib by activation of NF-
ΚB through Raf/MEKK1 and PI3-K/Akt pathways [4,41].
Study of Wang et al. and Zang et al. showed bone mar-
row stromal cells (BMSCs) regulate the drug sensitivity
of myeloma cells through the inhibited expression of
miRNA and IL-6 plays a pivotal role in the occurrence
of drug resistance [42,43]. IGF-1 produced by plasma
cells, as well as by the marrow microenvironment, is a
critical mediator of a number of downstream effects that
contribute to multiple myeloma pathobiology. The IGF-
1 receptor has been found to be over-expressed in mye-
loma and this aberrant expression, as well as higher
IGF-1 levels, have been related to disease progression,
severity, and prognosis [44-46]. Studies of Kuhn et al. re-
vealed evidence that increased IGF-1 signaling through
enhanced IGF-1 secretion and IGF-1R activation was as-
sociated with the phenotype of resistance in bortezomib-
resistant cell lines selected from RPMI 8226, OPM-2,
ANBL-6, and KAS-6/1 myeloma cell lines by bortezomib
exposure and no PSMB5 mutations were found in these
bortezomib-resistant cell lines. Additionally, gene ex-
pression profiling confirmed that genes acutely activated
by IGF-1 stimulation were chronically expressed in
bortezomib-resistance cell lines. Furthermore, blockade
of downstream targets such as PI3K and mTOR could, to
some extent, overcome this resistance. Pharmacologic or
genetic suppression of IGF-1R also sensitized cell lines and
patient samples to bortezomib therapy. Finally, the IGF-1R
inhibitor OSI-906 synergized with bortezomib to enhance
myeloma cell death and overcame bortezomib-resistance
in vivo. Thus, these data strongly implicate that signaling
through the IGF-1/IGF-1R axis contributes to acquired
bortezomib resistance, and provide a rationale for combin-
ing bortezomib with IGF-1R inhibitors likely to overcome
or possibly prevent the emergence of bortezomib resist-
ance [47].
Study of Que et al. showed c-Met, a receptor tyrosine
kinase, is over-expressed in human myeloma cell lines
and promotes the survival and drug resistance of mye-
loma cells. This study confirmed knockdown of c-Met
enhances sensitivity to bortezomib in human multiple
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[48]. Kim et al. generated bortezomib-resistant mantle
cell lymphoma cell lines and found increased phospho-
rylation of Akt and mTOR. Dual inhibition of PI3K and
mTOR with BEZ235 could overcome acquired resistance
to bortezomib in mantle cell lymphoma cells and sup-
press the activated Akt/mTOR pathway [49].
Moreover, microarray analysis revealed that the mRNA
levels of Rad (Ras associated with diabetes) were higher in
the bortezomib-resistant Jurkat-R cells than in the paren-
tal control cells. Rad knockdown overcame bortezomib re-
sistance and induced mitochondrial apoptosis via Noxa/
Bcl-2 modulation. Rad decreased cell death in response to
bortezomib. Leukemia and lymphoma cell lines (K-562,
Raji, IM-9 and Jurkat-R) with elevated Rad expression
levels showed higher degrees of bortezomib resistance ver-
sus those (Sup-B15, JVM-2, U266 and Jurkat) with low
Rad expression levels [50]. Study of Gu et al. demon-
strated that myeloma differentiation status is associated
with myeloma sensitivity to bortezomib and that induc-
tion of differentiation, increasing the proteasome work-
load in myeloma cells by increasing immunoglobulin
secretion, while reducing proteasome capacity by de-
creasing proteasome activity, can overcome myeloma
resistance to bortezomib [51]. Jung et al. reported that
stem-like cells in mantle cell lymphoma, termed mantle
cell lymphoma-initiating cells, enriched in the popula-
tion that lack prototypic B-cell marker CD19. These
cells were able to self-renew upon serial transplantation
and are highly tumorigenic. Importantly, these stem-like
cells are resistant to bortezomib, as well as chemothera-
peutic regimens containing bortezomib, despite constitu-
tive NF-κB expression [52]. Molecules targeting these
spots prospectively overcome bortezomib resistance and
possibly prevent the emergence of bortezomib-refractory
disease in the clinic.
Multi-drug resistance (MDR)
In our previous study, no cross-resistance to anthracycline,
alkaloid, or topoisomerase inhibitor drugs was displayed
in bortezomib-resistant JurkatB cell lines. The result of
a flow cytometric assay utilizing daunorubicin (DNR)
suggested that the bortezomib-resistant JurkatB cells
did not gain drug efflux function. Meanwhile, expres-
sion of P-glycoprotein (P-gp) was not detected in all
JurkatB lines by western blot. No significant differences
of mRNA expression levels of MDR1, lung resistance-
related protein (LRP), multi-drug resistance-associated
protein (MRP) genes were shown between JurkatB and
Jurkat cells. We thus concluded that MDR is unlikely to
account for the aquired bortezomib resistance in JurkatB
lines, which is similar to the results observed in the pri-
mary bortezomib resistant SUDHL-4 B-lymphoma cells
[29,37]. De Wilt et al. also found no cross-resistance to aprototypical P-gp substrate (i.e. DNR) and differences in
functional P-gp activity between parental and bortezomib
resistant cells, suggesting that enhanced drug efflux via
MDR transporters does not contribute to bortezomib re-
sistance in NSCLC cells [21].
Our previous study showed a significant cytotoxicity of
bortezomib on a P-gp positive leukemia line K562/A02
cells, but the effect on K562/A02 cells was significantly
decreased compared to that on K562 cells. The resistance-
fold of K562/A02 cells to bortezomib compared with
K562 cells is much lower than to anthracycline. The
resistance-fold of K562/A02 to adriamycin and DNR were
139 and 67 compared with K562 cells, while the
resistance-fold of K562/A02 to bortezomib was only 3
compared with K562 cells. These results showed only a
slight cross-resistance of K562/A02 to bortezomib [53].
Lymphoid CEM/VLB cells with P-gp overexpression
exhibited substantial resistance to carfilzomib (114-fold),
whereas less resistance to bortezomib (4.5-fold) was ob-
served [54]. Minderman et al. showed that among P-gp,
breast cancer resistance protein and LRP, only P-gp con-
ferred resistance to bortezomib, and the resistance was
only two-fold [55]. Rumpold et al. showed that knock-
down of MDR1 resensitizes leukemic cells to bortezomib,
suggesting bortezomib is also a P-gp substrate, which
might be relevant for drug-resistance in cancer [56].
To sum up, though drug extrusion via the multidrug
efflux transporter P-gp has been shown to mediate a low
level of bortezomib resistance, MDR may be not the
overwhelming mechanism of bortezomib resistance.
Conclusions
The mechanism of proteasome inhibitor bortezomib re-
sistance mainly focused on the modifications of the me-
chanisms of its action. The possible bortezomib resistance
mechanism can be summarized as Figure 4.
Bortezomib mainly reversibly inhibit the chymotrypsin-
like activity at the PSMB5 and to a lesser extent inhibit
the trypsin-like activity at the β1 subunit. The mutation
and over-expression of β subunits is a hotspot in the study
of bortezomib resistance. Our previous study and other
teams’ studies demonstrated point mutations of PSMB5 is
an important mechanism of bortezomib resistance. The
majority of the mutations reside around the S1 specificity
pocket of the PSMB5. The Thr21Ala, Ala49Thr and
Ala50Val substitutions in the bortezomib-binding pocket
in the PSMB5 are directly involved in bortezomib binding
to PSMB5. Cys52Phe, Met45Ile substitutions in close pro-
ximity to the bortezomib-binding pocket in the PSMB5 are
indirectly involved bortezomib binding. The Cys63Phe mu-
tation housed in the same helix as Ala49/50 leads to a shift
in the angle of the helix with respect to the active site,
therefore, likely affects the binding of bortezomib to
PSMB5. Silico data suggest that all acquired mutations
Figure 4 The summary of possible bortezomin resistance mechanisms. The mechanisms of proteasome inhibitor bortezomib resistance
mainly focused on the modifications of the mechanisms of its action. Mutations at key points of β5 subunit of proteasome (PSMB5) decrease the
affinity of the PSMB5 to bortezomb, which result in the decreased inhibition of the chymotrypsin-like activity, up-regulation of proteasome
subunits contributing to the high basal levels of proteasome activity, alterations of gene and protein expression in stress response and cell
survival, antiapoptotic pathways are important mechanisms of bortezomib resistance. Efflux transporter P-gp was also shown to mediate a certain
degree bortezomib resistance.
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in the decreased inhibition of the chymotrypsin-like acti-
vity, then displayed bortezomib resistance [16-21]. Further-
more, studies have demonstrated that overexpression of
the PSMB5 gene and the up-regulation of proteasome
subunits contributing to the high basal levels of prote-
asome activity correlate with acquired and intrinsic
bortezomib resistance.
The results of these studies are important for the
design of novel proteasome inhibitors without cross-
resistance with bortezomib. Proteasome inhibitors specific
for other subunits, such as the novel α7-subunit-specific
proteasome inhibitor 5-HAQ, have been reported to be
susceptible to tumor cells with β5 subunit up-regulation
or mutation. Moreover, resistance to bortezomib can be
partially overcome with irreversible inhibitor carfilzomib.
In addition, inhibition of the ubiquitination pathwayenzyme is also a novel strategy to overcome bortezomib
resistance.
The anti-tumor effects of bortezomib are a result of cell
cycle arrest and apoptosis resulting from blocking the
degradation of the poly-ubiquitinated proteins after prote-
asome inhibition. The underlying mechanisms include NF-
κB inhibition, upregulation of various apoptotic pathways,
downregulation of antiapoptotic pathways and effects on
the tumor microenvironment. So, alterations of gene and
protein expression in stress response and cell survival,
antiapoptotic pathways are also important mechanisms of
bortezomib. For example, upregulation of HSPs, IL-6, IGF-
1/IGF-1R, c-Met, Rad, β-catenin/Wnt and Akt/mTOR
pathways were confirmed to be associated with bortezomib
resistance. Molecules targeting these spots prospectively
overcome bortezomib resistance and possibly prevent the
emergence of bortezomib-refractory disease in the clinic.
Lü and Wang Biomarker Research 2013, 1:13 Page 8 of 9
http://www.biomarkerres.org/content/1/1/13At last, MDR have been confirmed not to be the over-
whelming mechanisms of bortezomib resistance in many
studies. But in some other studies drug extrusion via the
multidrug efflux transporter P-gp has been shown to
mediate a low level of bortezomib resistance.
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